

Subject index

A

A-947864, 178 (566)
17-AAG, 49 (154)
ABCG2, 160 (503)
ABI-013, 142 (453)
Abiraterone acetate, 12 (26), 39 (118), 51 (158, 159), 81 (2LB)
Abstract quality assessment, 120 (382)
ABT-263, 14 (34), 85 (261)
ABT-888, 175 (555)
Accelerator mass spectroscopy (AMS), 10 (20)
Acetylation, 111 (350), 142 (452)
Actinomycin D, 42 (131)
Acute lymphoblastic leukaemia (ALL), 8 (12), 60 (190), 61 (193), 63 (198), 87 (267), 92 (286), 161 (507), 173 (549)
Acute myeloid leukaemia (AML), 86 (266), 150 (471), 153 (478), 161 (506)
Acute promyelocytic leukaemia (APL), 86 (264)
Adenoid cystic carcinoma (ACC), 26 (75), 65 (206)
Adrenocortical carcinoma, 115 (365)
AF1q, 156 (491)
AKT, 32 (94)
Akt pathway, 155 (486)
ALB 109564, 141 (449)
Alpha-enolase, 34 (101)
AMG 479, 162 (509)
Amphiregulin, 31 (92)
AMPK pathway, 27 (78)
Anaplastic large cell lymphoma (ALCL), 73 (233), 95 (295)
Androgen receptor inhibitors, 50 (157), 51 (160), 52 (161, 162)
Andrographolide derivatives, 43 (132)
ANG1005, 133 (424, 425)
Angiogenesis, 16 (41), 17 (42, 43, 44), 18 (45, 46, 47, 48), 20 (54), 21 (59), 22 (60, 63), 26 (76), 55 (171), 71 (226, 227), 73 (232), 92 (284), 106 (335), 111 (352), 114 (360), 130 (414), 174 (553), 181 (576)
Angiopep-2, 133 (424, 425)
Animal models, 4 (5), 7 (10, 7, 9), 18 (48), 21 (57), 23 (64, 65, 66), 24 (68, 69), 25 (72), 26 (73, 76), 29 (85), 38 (114), 39 (119), 41 (125), 46 (144), 49 (152), 52 (163), 53 (165, 167), 57 (180), 59 (187), 80 (244), 95 (297), 96 (299), 99 (308, 309), 105 (330), 107 (338), 108 (340), 110 (347), 115 (365), 117 (371), 119 (380), 141 (450), 142 (451, 454), 151 (474), 160 (504), 163 (513), 164 (518), 166 (525), 167 (528, 529), 169 (533), 170 (539), 171 (540), 172 (547), 179 (569), 181 (577, 578), 188 (602)
 pitfalls, 7 (8)
Annexin I, 118 (375)
Annexin IV, 158 (495)

Annexin V, 148 (462)
 radiolabelled, 148 (462)
Ansamycin derivatives, 48 (148), 49 (153)
Anti-cachexia, 107 (338)
Anti-inflammatory agents, 172 (547)
Antibody arrays, 111 (351)
Antibody conjugates, 149 (464, 465), 161 (507), 163 (514), 164 (518), 166 (523, 525), 167 (527, 529), 169 (533), 171 (540)
Antibody drugs, 149 (466), 160 (504), 161 (508), 163 (513), 164 (516, 519), 171 (540)
Antisense oligonucleotide (ASO), 125 (399)
AP24534, 174 (553)
APO866, 116 (367)
Apollon gene, 84 (256)
Apoptosis, 56 (175), 72 (228, 230), 73 (232), 84 (257, 258), 85 (260, 261, 262), 86 (264, 265, 266), 87 (267, 268), 88 (270, 273), 89 (274, 276, 277), 90 (278), 94 (291, 292), 95 (295), 98 (307), 106 (333), 110 (347), 112 (353, 354), 113 (356), 115 (364), 118 (377), 128 (407), 136 (432), 139 (444), 151 (472), 156 (491), 157 (493), 161 (506), 179 (572), 187 (598)
 imaging, 148 (462)
 induction, 45 (141)
AR36A36.11.1, 164 (517)
AR40A746.2.3, 161 (506)
AR47A6.4.2, 117 (371), 165 (520)
Arf6, 20 (54)
ARH460-16-2, 170 (538)
ARQ197, 121 (386)
ARRY-520, 140 (447)
ARRY-768, 181 (576)
Arsenic trioxide, 86 (264)
AS1411, 88 (272)
ASA404, 32 (96)
AST, 179 (572)
Astrocytomas, 57 (178)
AT13387, 47 (147)
AT9283, 93 (287)
AT-101, 66 (209)
ATP-competitive inhibitors, 136 (433)
Attrition rates in oncology, 14 (35)
Aureolic acid derivatives, 58 (182)
Auristatin, 161 (507), 167 (527)
Aurora, 136 (432)
Aurora A, 8 (12), 9 (14), 32 (93), 37 (113), 79 (243), 90 (279, 280), 91 (281, 282, 283), 92 (284, 285, 286), 93 (287, 289, 290), 130 (415)
Aurora B, 79 (243), 91 (282, 283), 93 (287, 288, 290)
Aurora C, 79 (243), 91 (283), 93 (290)
Authorisation, 8 (11)

Autocrine signaling, 96 (298)
Autophagy, 16 (40), 79 (239, 240, 241, 242), 84 (257), 88 (271), 108 (341)
AVE 1642, 177 (562)
AVN944, 151 (472)
AZ-23, 180 (574)
AZD0530, 27 (77), 123 (391), 180 (575)
AZD1152, 93 (288)
AZD2281, 175 (557)
AZD55097, 94 (292)
AZD6244, 29 (84), 86 (265), 111 (349), 113 (358)
B
13B8.2, 168 (532)
B-RAF inhibitors, 183 (584)
B-RAF mutations, 120 (383)
B-RAF V600E, 81 (247), 178 (567), 183 (587), 185 (591)
Bad, 112 (354)
BAL27862, 139 (444)
BCA2 inhibitors, 44 (135)
Bcl-2, 17 (44), 85 (261), 87 (267), 88 (272), 97 (303), 185 (592)
Belinostat, 67 (213), 127 (404), 132 (419, 420)
Benzamide riboside, 110 (348)
Berubycin, 187 (600)
Bevacizumab, 14 (33), 18 (45), 185 (591)
BH4 domain, 17 (44)
BH3 mimetic, 115 (364)
BI 6727, 14 (36), 135 (430)
Bicalutamide, 103 (324)
BIIB021, 50 (156)
Biliary cancer, 126 (402)
Bim, 86 (266)
Bioavailability, 24 (69), 25 (72), 44 (136), 47 (146), 48 (150), 49 (153), 70 (223), 94 (291), 102 (322), 105 (332), 106 (335), 108 (339, 341), 116 (368), 123 (393), 134 (426), 136 (434), 154 (482), 175 (555), 177 (561), 179 (571), 180 (574)
Bioinformatics, 9 (17)
Biomarkers, 9 (14), 13 (31), 19 (51), 27 (77), 28 (83), 30 (89), 32 (95), 33 (99), 37 (112), 62 (195), 70 (223), 74 (235), 105 (331), 108 (342), 115 (363), 118 (376), 147 (457), 158 (495)
 correlation analysis, 30 (87)
Bioreductive agents, 151 (473, 474)
Bladder cancer, 35 (106), 63 (200), 67 (213), 97 (304)
Blood–brain barrier, 38 (117), 45 (139), 57 (180), 133 (424, 425), 187 (600)
BMS663513, 169 (534)
BMS-641988, 50 (157)
BMS-690514, 123 (392)
BMS-777607, 176 (560), 179 (569)
BN83495, 52 (163)
Bortezomib, 15 (38), 24 (68), 49 (152), 73 (232, 233), 156 (490)
Brain metastases, 160 (505)
Brain tumours, 38 (117), 45 (139)
BRCA2, 25 (71)
BRCA mutations, 80 (245), 175 (557)
Breast cancer, 4 (6), 12 (27), 16 (39), 18 (45, 46), 20 (53, 54), 21 (58), 25 (71), 36 (107, 110), 52 (163, 164), 53 (167), 56 (175), 58 (183, 184), 72 (229), 89 (275), 104 (327), 114 (361), 118 (375), 140 (445), 147 (457), 154 (483), 155 (485), 158 (497), 161 (506), 165 (520, 521), 175 (555), 176 (559), 182 (580), 184 (589), 187 (599)
 ER + , 155 (488)
 metastatic, 131 (416)

 triple negative, 175 (557)
Brivanib alaninate, 135 (429)
Burkitt's lymphoma, 97 (303)
BYK408740, 123 (393)

C

c-kit, 19 (50), 65 (206)
c-Met inhibitors, 28 (81), 121 (386), 129 (411), 177 (563)
C-Met pathway, 3 (4)
c-myc, 173 (548)
Camptothecins, 138 (441), 186 (594)
CanAg, 163 (514)
Cancer cell lines, 8 (12, 13), 11 (25), 14 (33, 34), 16 (39), 17 (44), 18 (45, 46, 47), 21 (56, 58, 59), 22 (62), 23 (66), 24 (68), 25 (70, 71), 26 (73), 27 (80), 28 (83), 29 (84), 30 (87, 88), 31 (91), 32 (94), 33 (99), 36 (110), 37 (111), 40 (122), 42 (129), 47 (146, 147), 48 (151), 50 (157), 52 (161), 53 (167), 55 (173), 57 (178, 181), 58 (183, 184), 59 (185, 187), 60 (191), 61 (192), 62 (197), 80 (245), 83 (252), 85 (261, 262), 86 (264), 87 (269), 88 (271), 89 (275, 276), 93 (288), 95 (297), 96 (299, 300), 97 (304), 99 (310), 100 (312), 101 (316, 317), 103 (323), 104 (328), 106 (333, 334), 107 (336), 108 (340), 111 (349, 351), 112 (354), 113 (356, 357), 114 (361), 116 (369), 118 (375, 376, 377), 128 (407), 137 (437), 139 (442, 443), 150 (470), 151 (472, 473), 153 (479), 155 (486, 487), 156 (490, 491), 157 (492), 158 (496, 498), 159 (499, 501), 161 (508), 166 (524), 168 (531), 169 (534, 536), 170 (538), 171 (540), 172 (546), 175 (557), 176 (558, 559, 560), 177 (562), 179 (572), 181 (579), 182 (580), 183 (586), 184 (590), 186 (596), 187 (597, 598, 600)
Cancer mechanisms, 22 (60, 62), 101 (316), 104 (327), 110 (346), 111 (351), 153 (479), 156 (490), 157 (494)
Capecitabine, 126 (402), 185 (591)
Carboplatin, 67 (213), 132 (419)
Carfilzomib, 75 (238), 121 (385)
Casearia capitellata, 58 (183)
Casein kinase, 156 (489)
Casopitant, 124 (396)
Caspase, 88 (270)
Caspase-3, 84 (256), 112 (354)
Caspase-7, 87 (268)
Caspase-8, 84 (259)
C57BL6 mice, 23 (66), 32 (96), 38 (114), 41 (125), 43 (133), 99 (308)
CD30, 166 (523)
CD56, 162 (510)
CD59, 164 (517)
CD antibodies, 160 (504), 161 (506, 507), 167 (526), 168 (532), 169 (534), 170 (538)
CD expression, 118 (378)
Cdc7, 116 (368)
Cdc inhibitors, 108 (339)
CDK inhibitors, 94 (291, 292, 294), 95 (295)
Cediranib, 124 (394), 180 (575)
Celecoxib, 122 (389)
Cell adhesion molecules, 37 (112)
Cell-based analysis, 42 (128)
Cell cycle, 14 (36)
Cell-cycle arrest, 12 (27), 32 (93), 35 (104), 42 (131), 43 (132), 48 (151), 56 (177), 70 (221), 72 (231), 73 (232, 233), 79 (243), 80 (244), 83 (254), 84 (258), 88 (270, 272), 89 (276), 93 (288, 290), 94 (292), 107 (337), 108 (339), 153 (481), 179 (572), 181 (577)
Cell differentiation, 117 (373)

Cell migration, 96 (298), 106 (335), 172 (545), 178 (568)
Cell proliferation, 86 (263), 88 (273), 89 (277), 92 (284), 94 (291), 96 (298), 101 (317), 106 (335), 107 (337), 111 (352), 179 (571)
Cell surface proteins, 36 (110)
Cellular dynamics, 94 (293)
Cellular uptake, 39 (120), 40 (122, 124)
CENP-E inhibitors, 107 (337), 108 (342)
Ceramide release, 168 (532)
Cervical carcinoma, 66 (208), 118 (378)
Cetuximab, 27 (79), 33 (98), 81 (247), 116 (370), 149 (467), 164 (516)
Chalcone derivatives, 56 (177)
Chemical biology, 15 (37)
Chemoprevention, 35 (106)
Chemoresistance, 87 (268)
Chemotherapy, 3 (2), 11 (25), 22 (63), 25 (71), 26 (75), 36 (108), 51 (158), 59 (186), 61 (194), 69 (220), 72 (230), 75 (238), 95 (295), 107 (336), 112 (353), 124 (395), 126 (403), 129 (412), 131 (417), 137 (435), 142 (453), 157 (493), 164 (518), 166 (523), 167 (526)
Chk inhibitors, 124 (395)
Chlorambucil, 46 (142)
2-Chloroadenosine, 83 (255), 84 (258)
Chloroquine, 84 (257)
CHR-2797, 109 (344)
Chronic lymphocytic leukaemia (CLL), 82 (249), 161 (507)
Chronic myelogenous leukaemia (CML), 88 (271), 110 (348), 181 (578)
CHS-828, 116 (367)
Circulating tumour DNA, 33 (97)
Cisplatin, 35 (104), 60 (190), 63 (200), 65 (207), 99 (308), 138 (439), 159 (502)
Clear cell carcinoma, 158 (495)
Clerodane diterpenes, 58 (183)
Clinical chemistry, 37 (112)
Clinical response evaluation, 13 (32)
Clofarabine, 151 (472)
CNS tumours, 57 (180)
Colon cancer, 9 (18), 18 (46), 27 (79), 38 (114, 115), 84 (257), 89 (276), 107 (336), 113 (357), 118 (376), 141 (448), 158 (496), 165 (520), 179 (572), 183 (586), 185 (593), taxane resistant, 135 (430)
Colorectal cancer, 27 (80), 29 (84), 31 (91, 92), 32 (94), 33 (98), 47 (145), 55 (171, 172), 64 (202), 65 (205), 67 (210), 81 (247), 89 (274), 92 (284), 111 (349), 115 (363, 366), 116 (370), 158 (498), 169 (536), 174 (551), 185 (591), 187 (597), 188 (601)
Combination therapies, 7 (7), 15 (38), 20 (53, 55), 21 (59), 31 (90), 32 (96), 38 (116), 40 (123), 50 (156), 52 (161), 54 (168), 55 (174), 57 (179), 60 (190), 63 (200), 64 (204), 65 (205, 207), 66 (209), 67 (210, 211, 213), 69 (220), 72 (229), 73 (232, 233), 75 (238), 79 (242), 85 (260), 86 (265), 97 (303, 304), 99 (308), 100 (313, 314), 103 (323, 324, 325), 104 (328, 329), 107 (336), 109 (344), 111 (349), 112 (353), 115 (364), 116 (370), 124 (395, 396), 126 (401, 403), 128 (408), 129 (410, 412), 131 (417), 132 (419, 420), 134 (428), 137 (435), 138 (439, 441), 141 (450), 142 (451, 452), 150 (469), 151 (472), 153 (480), 154 (482), 155 (486), 157 (492), 159 (502), 160 (505), 162 (512), 163 (515), 165 (520), 166 (523), 168 (530), 171 (541), 175 (556), 176 (558), 178 (565, 568), 180 (575), 182 (581), 185 (591, 593), 186 (594, 596)
Combretastatin, 142 (454)
Complement dependent cytotoxicity (CDC), 167 (526)
Computer-aided design, 43 (134)

Computer-aided treatment ordering, 61 (194)
Combination therapies, 21 (57)
Continuous Reassessment Method (CRM), 14 (34), 121 (387)
COX-2, 35 (106)
CP-4055, 150 (471)
CP-751,871, 122 (388), 178 (565)
CP-868,596, 183 (585)
CS-7017, 128 (409)
CTCE-9908, 127 (405)
CU-0305, 47 (146)
Culture models, 95 (296)
Curcumin analogues, 90 (278)
Cutaneous T-cell lymphomas, 118 (377)
CX-5461, 108 (341)
CXCR inhibitors, 52 (164), 127 (405)
Cyber-infrastructure, 9 (17)
Cyclophosphamide, 60 (190)
CYP, 105 (331), 106 (334)
CYP inhibitors, 12 (26, 27), 51 (158, 159)
CYP pathway, 11 (24)
Cytokines, 22 (63), 41 (125), 83 (255), 172 (547)

D

D-3263, 109 (343)
DACH, 35 (104)
DAPK gene, 29 (86)
Darinaparsin, 86 (264)
Data processing, 42 (128)
DB293 derivatives, 152 (477)
DCE-MRI studies, 16 (41)
Deforolimus, 102 (321), 103 (324)
Dexamethasone, 15 (38), 24 (68), 124 (396)
2-DFG, 88 (273)
Differentiation, 152 (475, 476)
Diffuse large B-cell lymphoma (DLBCL), 29 (86)
Disease progression, 26 (76), 115 (366), as endpoint, 13 (32)
Dishevelled PDZ domain, 137 (436)
DNA damage, 187 (598, 599)
DNA double-strand break, 41 (127)
DNA helix stabilisation, 60 (189)
DNA repair, 152 (477), 153 (478, 479, 480, 481), 154 (482, 483), 155 (486), 175 (555)
Docetaxel, 66 (209), 67 (211), 75 (238), 83 (255), 124 (396), 141 (450), 142 (453), 143 (455), 157 (493), 163 (515), 178 (565), 184 (588), 185 (592), pegylated, 141 (448)
Dose escalation, 14 (36), 16 (41), 17 (42)
Dose finding studies, 14 (34)
Doxicycline, 26 (74)
Doxil, 75 (238), 143 (455)
Doxorubicin, 40 (122), 132 (420), 156 (491), cardiotoxicity, 119 (380), liposomal, 162 (512)
Drug delivery, 38 (117), 39 (118, 119), 40 (121, 123), 41 (125), 45 (139), 97 (301), 98 (305), 147 (456), 173 (550), using nanoparticles, 40 (124)
Drug development, 3 (1), 7 (9), 10 (20, 21), 11 (24, 25), 13 (31), 30 (87, 88), 43 (134), 57 (181), 60 (190), 88 (272), 90 (278), 94 (293), 147 (460), 149 (464, 465, 467), 150 (470), 157 (493), 173 (550), paediatric, 8 (11, 12, 13), 9 (15)
Drug discovery, 7 (8), 11 (22), 42 (128), 43 (133), 94 (291), 97 (302), 102 (322), 105 (331), 107 (336), 116 (368), 135 (430), 136 (432, 433), 165 (522), 166 (524), 171 (543), 172 (544), 176 (560), 177 (561), 183 (584)

Drug management, 61 (194)

Drug resistance, 79 (240), 155 (485, 487), 156 (490), 157 (492, 493, 494), 158 (495, 496, 497, 498), 159 (499, 501, 502), 160 (503), 161 (507), 162 (512), 163 (515), 164 (518, 519), 172 (545), 174 (552), 175 (555), 177 (563), 182 (582), 183 (586), 187 (597)

mechanisms, 147 (457)

Drug screening, 43 (134), 59 (185, 188), 108 (339), 109 (343), 133 (424, 425), 136 (434), 139 (442), 149 (466), 165 (522), 171 (543), 180 (573)

Drug synthesis, 44 (135, 136), 45 (138, 140), 74 (237), 93 (287), 98 (305), 106 (334), 129 (411), 137 (436), 176 (560)

DUSP4, 33 (98)

E

E7080, 53 (165)

E7389, 131 (417), 140 (446)

EGF, 126 (402)

EGFR, 24 (69), 25 (72), 27 (79), 30 (87), 31 (90, 92), 33 (97), 34 (103), 53 (167), 62 (196), 80 (246), 87 (269), 99 (309), 100 (313), 101 (315, 318), 103 (325), 155 (485), 160 (505), 164 (516), 168 (530), 169 (536), 174 (552), 177 (563), 178 (566), 184 (588)

EGFR antibodies, 171 (541)

EGFR mutations, 68 (215), 69 (219), 119 (381), 154 (484), 155 (487), 170 (537)

EGFR–MAPK pathway, 177 (564)

EKB-569, 176 (559)

eIF4, 83 (252, 253)

eIF5, 96 (299)

EM164, 177 (562)

EMT, 54 (169, 170), 152 (475)

Endometrial cancer, 36 (109)

Endothelial adhesion molecules (EAM), 21 (57)

Endothelin A, 54 (168)

ENMD-2076, 92 (284)

Enzastaurin, 65 (205), 126 (401), 132 (421), 157 (494)

Ependymomas, 81 (248)

Eph kinases, 57 (178)

Epiregulin, 31 (92)

ER α , 182 (580)

ErbB2, 178 (566)

ErbB2/HER2 inhibitors, 99 (310)

ErbB inhibitors, 97 (302), 99 (311), 100 (312, 313, 314), 101 (317)

ErbB3/PI3K/Akt pathway, 176 (559)

ErbB receptor inhibitors, 184 (590)

ErbB/VEGF receptors, 123 (392)

inhibitors, 123 (392)

Eribulin mesylate, 140 (446)

ERK activation, 29 (84), 56 (175), 86 (265, 266), 99 (311), 120 (383), 179 (572)

ERK inhibitors, 33 (98)

ERK phosphorylation, 182 (582)

Erlotinib, 25 (72), 38 (116), 68 (215), 103 (325), 104 (328), 119 (381), 123 (392), 126 (401), 129 (410), 175 (556), 184 (588)

ES-285, 56 (176)

ESE-3, 139 (443)

ESI-TOF, 46 (142)

Estradiol, 89 (275)

Ewing's sarcoma, 122 (388)

EZN-2208, 134 (427)

EZN-2968, 125 (398)

EZN-3920, 100 (312)

F

F14512, 37 (111)

6F4, 172 (544)

F3-2-5, 88 (270)

FasL, 112 (354)

FASN inhibitors, 184 (590)

Fatty acid synthase (FASN), 115 (363)

FAU, 150 (468)

FDG-PET, 108 (342)

Fenretidine, 73 (232)

FGFR4 Y367C mutation, 114 (361)

Filopodia, 59 (186)

First-in-human studies, *see* **Phase 0 studies**

Flavopiridol, 73 (233), 95 (295)

FLT-PET, 113 (358)

Focal adhesion kinase, 43 (133)

Food intake, 134 (426), 135 (429)

pharmacokinetic effects, 134 (426), 135 (429)

5FU, 9 (18), 38 (115), 62 (197), 67 (210), 113 (357), 158 (496)

Fusicochin derivatives, 59 (187)

G

12G4, 163 (513)

GA101, 160 (504)

GAPDH, 159 (500)

Gastric cancer, 34 (100), 54 (169, 170), 163 (514)

Gastrointestinal cancer, 22 (60), 97 (301)

Gastrointestinal stromal tumours (GIST), 67 (212), 117 (372), 182 (583)

GDC-0449, 112 (355)

GDC-0941, 69 (217, 220), 70 (223)

Gefitinib, 65 (207), 119 (381), 154 (484), 155 (487), 157 (492)

Gemcitabine, 68 (214), 104 (328), 124 (395), 126 (402), 131 (417), 159 (499), 165 (520), 171 (541)

Gene analysis, 62 (195, 196), 153 (481), 160 (503)

Gene array analysis, 29 (84)

Gene expression analysis, 42 (131), 65 (207), 182 (580), 184 (589)

Gene expression profiling, 34 (102), 64 (202), 72 (231), 169 (534)

Gene polymorphisms, 62 (196), 63 (198, 199, 201)

Gene profiling, 42 (128)

Gene signatures, 27 (79)

Gene silencing, 173 (548), 174 (551)

Gene therapy, 98 (305, 306)

Genetic engineering, 7 (8), 58 (182)

Genetic screening, 147 (457, 458)

Genome-wide association studies (GWAS), 10 (19)

Genomics, 7 (10)

Genotype–phenotype association, 9 (16)

Genotyping, 10 (19)

Germline variants, 9 (16)

Ghrelin, 107 (338)

GI-4000, 28 (82)

Gimatecan, 186 (596)

Glioblastoma, 40 (123, 124), 55 (174), 57 (178), 72 (230), 95 (296)

Glioblastoma multiforme (GBM), 172 (545), 187 (600)

Gliomas, 88 (273), 153 (479), 159 (499), 168 (530), 172 (546)

Glucopiericidin A, 59 (186)

Glutathione transferases, 158 (496)

Glycoengineering, 160 (504)

Glycolysis, 88 (273)

Glycosylation, 117 (372)

GMX1777, 131 (418), 150 (470)

Granulosa cell tumours, 163 (513)

Green tea, 38 (116)
GRN163L, 138 (438)
GSK1120212, 33 (99), 178 (567)
GSK461364, 135 (431)
GSK615, 70 (221)
GSK923295A, 125 (397)
GSK923925A, 107 (337), 108 (342)
Guanidine exchange factor 16, 37 (113)
Guanine quadruplexes, 116 (369), 138 (441)
GW2974, 27 (78)

H

Hdm2 inhibitor, 81 (1LB)
Head and neck cancer, 27 (79), 38 (116), 65 (207)
Hedgehog signaling, 112 (355), 179 (570)
Hepatocellular carcinoma, 17 (43), 20 (52)
HER, 30 (88), 34 (103), 99 (309), 101 (315), 120 (383), 155 (485)
HER1, 80 (246)
HER2, 99 (311), 100 (314), 101 (318), 188 (602)
Her2-luciferase, 48 (150)
Herceptin, 72 (229)
HIF, 20 (53), 71 (224), 72 (229)
HIF-1, 17 (44), 125 (398), 185 (593)
HIF-1a, 101 (316)
Histone deacetylase inhibitors, 23 (66), 28 (83), 44 (136), 48 (149), 59 (185), 84 (259), 108 (340), 111 (350), 123 (393), 127 (404), 130 (413), 133 (422), 142 (452), 150 (469)
hMLH1 mutations, 38 (115)
hnRNP, 43 (134)
Hodgkin lymphoma (HL), 166 (523)
HP1 γ , 117 (373)
Hsp90 inhibitors, 15 (37), 45 (140), 46 (144), 47 (145, 146, 147), 48 (148, 149, 150), 49 (152, 153), 50 (155, 156)
HT10, 21 (59)
Human leukocyte antigen (HLA), 24 (68), 36 (107)
Human myeloblastic leukaemia (HML), 152 (476)
HUVECs, 19 (51)
Hypermethylation, 29 (86), 36 (109), 55 (174)
Hypoxia, 17 (44), 22 (60), 23 (65), 96 (300), 101 (316), 129 (412), 159 (499)
 imaging, 148 (461)

I

IAP inhibitors, 98 (307)
ID-1, 152 (476), 157 (493)
IDN6140, 57 (180)
IFG-I, 3 (2)
IFN γ -activated sequences (GAS), 114 (362)
IGF-1, 31 (91), 86 (263), 122 (390), 162 (509), 164 (516), 174 (554), 176 (558), 177 (562), 178 (565, 566)
IGF1R, 30 (87)
IgG1, 149 (467)
Imaging, 7 (10), 14 (33), 22 (61), 23 (65), 26 (76), 35 (105), 108 (342), 113 (358), 147 (460), 148 (463)
 apoptosis, 148 (462)
 hypoxia, 148 (461)
 live cells, 167 (526)
Imatinib, 67 (212), 88 (271)
IMC-A12, 164 (516), 174 (554), 176 (558)
IMC-D11, 63 (200)
IMC-18F1, 127 (406)
IMG-3G3, 162 (511)
IMG242, 163 (514)
IMG388, 167 (529)

IMGN901, 162 (510)
Immunoassays, 30 (88), 34 (103)
Immunocells, 113 (359)
Immunofluorescence, 95 (296)
Immunohistochemistry, 17 (44), 18 (46, 48), 21 (57), 27 (77), 28 (81), 34 (100, 102), 49 (154), 154 (483), 161 (508), 164 (517), 168 (531)
Immunostaining, 19 (51), 25 (71), 29 (84), 30 (89)
Immunotherapy, 21 (57), 28 (82), 35 (106), 36 (107)
Indole derivatives, 45 (141)
Inducible expression system, 155 (487)
Innovative Therapies for Children with Cancer (ITCC), 61 (193)
Integrins, 55 (171)
Interleukins, 22 (62), 23 (66), 41 (125), 64 (204), 116 (370), 128 (408), 158 (498)
Interstitial fluid pressure, 143 (455)
Ionomycin/PMA treatment, 89 (277)
IPI-493, 49 (153)
IPI-926, 179 (570)
Irinotecan, 133 (423), 182 (581), 185 (593)
Iron chelator, 187 (599)
ISIR-005, 59 (187)
Ixabepilone, 131 (416), 140 (445)

J

JAK2 inhibitors, 177 (561), 179 (571), 180 (573)
JAM-A, 165 (522), 172 (544)
Jurkat cells, 89 (277)

K

K-Ras mutations, 28 (82), 31 (92), 33 (97, 98), 36 (109), 81 (247), 120 (383), 181 (579)
KidsCancerKinome, 8 (13)
Kinase inhibitors, 14 (35, 36), 19 (50, 51), 21 (56), 24 (69), 25 (70, 72), 27 (78), 28 (81), 31 (90), 32 (93), 37 (113), 41 (127), 43 (133), 53 (165), 64 (203, 204), 66 (208), 68 (216), 69 (217, 218, 219, 220), 70 (221, 223), 71 (224, 225, 226, 227), 72 (228, 229, 230), 82 (250), 88 (271), 90 (279, 280), 91 (281, 282, 283), 92 (285), 93 (287, 288, 289, 290), 94 (294), 99 (311), 100 (314), 101 (318), 102 (319, 320), 103 (325), 104 (326), 105 (332), 109 (345), 114 (360), 119 (379, 381), 120 (383), 122 (390), 124 (395), 126 (402, 403), 129 (410), 130 (415), 134 (426), 135 (430, 431), 136 (432, 434), 155 (485), 157 (492), 168 (530), 170 (537), 171 (542), 174 (552, 553), 176 (560), 177 (561, 563), 178 (566, 568), 179 (569), 180 (574), 181 (576, 578), 182 (581, 582, 583), 186 (596)
'Kinase knockin' mice, 4 (5)
KIT, 182 (583)
KIT inhibitors, 67 (212)
KML001, 138 (439)
KSP inhibitors, 128 (407), 140 (447)
KU-0063794, 102 (319)

L

LA-12, 89 (276)
Lapatinib, 24 (69), 101 (318), 157 (492)
L1CAM, 110 (346)
Leptin, 32 (94)
Leucinoestrogens, 59 (188)
Leucovorin, 67 (210), 113 (357)
Leukaemia, 37 (111)
Library synthesis, 41 (127), 42 (130), 45 (141), 97 (302), 148 (463)

Linker design, 167 (527)
Lipid rafts, 148 (462), 168 (532), 184 (590)
Liposomal doxorubicin, 162 (512)
LIV-1 proteins, 184 (589)
Live-cell imaging, 167 (526)
Liver cancer, 41 (125)
Liver metastases, 64 (202)
Locked nuclear acid (LNA) technology, 97 (302, 303), 100 (312), 117 (374), 170 (537)
Lung cancer, 4 (6), 47 (147), 48 (151), 53 (165), 55 (173), 69 (219), 79 (242), 143 (455), 155 (487), 170 (537)
LY2275796, 125 (399)
Lymphoma, 57 (179), 128 (407)

M

Macrolactone derivatives, 45 (140)
Macrophages, 89 (274), 113 (359)
Magnetic resonance spectroscopy, 27 (80)
MALDI-TOF, 46 (142)
Malignant glioma, 133 (425), 186 (596)
Malignant melanoma, 22 (62), 23 (66), 27 (80), 47 (147), 56 (177), 90 (278), 95 (297), 99 (308), 106 (333), 107 (336, 338), 111 (352), 150 (470), 155 (486), 165 (521)
Malignant mesothelioma, 55 (173)
Malignant pleural mesothelioma (MPM), 32 (95)
MALT, 26 (74)
MAPK pathway, 44 (137), 182 (583)
mAR, 112 (354)
Mathematical models, 94 (293), 138 (440)
Matrix metalloproteinases, 122 (389)
Maytansinoids, 164 (518), 167 (529), 169 (533)
MCSP, 165 (521)
MDM2, 83 (254), 86 (266), 137 (435, 437)
Mdm2, 63 (201)
MDMX, 137 (437)
MDR transporters, 155 (488)
MDV3100, 51 (160)
ME1, 169 (536)
Mechanistic markers, 111 (350)
MEDI-575, 169 (535)
Medullary thyroid cancer (MTC), 119 (379)
Megakaryocyte potentiating factor (MPF), 32 (95)
MEK inhibitors, 29 (84), 33 (99), 44 (137), 86 (265, 266), 100 (313), 113 (358), 178 (567), 181 (577)
MEK2 mutation, 182 (582)
MEK signalling, 27 (80)
Membrane androgen receptor, 85 (262)
Mertansine, 163 (515)
Mesenchymal stem cells, 152 (475)
Mesothelin, 32 (95)
MET, 174 (552)
Met inhibitors, 176 (560), 178 (568), 179 (569)
Metabolic stress, 16 (40)
Metastasis, 37 (112), 52 (164), 53 (165, 167), 54 (168, 169, 170), 55 (171, 172), 59 (186), 64 (202), 101 (315), 111 (352), 129 (411), 130 (414), 133 (424), 135 (429), 171 (541), 175 (555), 178 (568), 180 (575)
 breast cancer, 131 (416)
2-Methoxyestradiol, 89 (275)
MetMAb, 129 (411), 167 (528), 170 (539), 175 (556)
MHC I, 171 (540)
MI-219, 83 (254), 137 (435)
Microarray analysis, 32 (94), 33 (98), 36 (110), 38 (114), 42 (131), 44 (135), 52 (162), 57 (178), 72 (228), 89 (275), 101 (316), 110 (348), 115 (363, 366), 116 (369),

118 (375), 119 (380), 147 (458), 152 (476), 154 (483), 159 (501), 163 (513), 165 (521), 174 (551), 183 (586), 185 (593)
Minimal residual disease (MRD), 173 (549)
miRNA, 117 (374), 159 (501)
Mismatch repair (MMR), 38 (115), 153 (478, 479)
Mitochondrial ATP synthesis, 53 (166)
 inhibition, 53 (166)
Mitotic checkpoints, 104 (327), 125 (397)
Mitotic delay, 93 (289)
Mitotic spindle, 136 (432)
MKK7, 183 (586)
MKP1, 107 (336)
MLC2, 109 (345)
MLN4924, 29 (85), 113 (356)
MLN8037, 92 (286)
MLN8054, 32 (93), 90 (279), 91 (281), 93 (289), 130 (415)
MLN8237, 90 (279, 280), 91 (281), 92 (285)
Molecular chaperones, 15 (37), 46 (144), 47 (145), 48 (149), 50 (155), 118 (378)
Molecular characterisation, 8 (12)
Molecular targets, 14 (35), 15 (37, 38), 16 (39), 20 (53), 79 (243), 80 (244, 246), 82 (249), 87 (267), 105 (331), 107 (336), 109 (343, 345), 111 (352), 114 (361), 115 (366), 116 (369), 117 (373), 158 (495), 165 (522), 182 (583)
Monocarboxylate transporters, 118 (378)
Monoclonal antibodies, 3 (4), 9 (18), 16 (41), 31 (90), 127 (406), 130 (414), 149 (467), 160 (505), 162 (509), 511, 164 (517), 165 (520, 521, 522), 166 (525), 167 (527, 528, 529), 168 (532), 169 (535, 536), 170 (539), 171 (543), 172 (544), 174 (554), 175 (556)
MP-470, 126 (403), 134 (426), 153 (480)
MPC-3100, 48 (150)
MR-1 inhibitors, 109 (345)
MRI, 148 (463)
mTOR, 104 (327)
mTOR inhibitors, 62 (195), 68 (216), 69 (219), 71 (224, 227), 82 (250), 102 (319, 320, 321, 322), 103 (323, 324, 325), 104 (326, 328), 105 (330), 179 (572), 185 (593)
Müllerian Inhibiting Substance, 163 (513)
Multilayered cell cultures, 168 (531)
Multiple myeloma, 15 (38), 24 (68), 25 (70), 96 (299), 140 (447), 156 (489, 490)
Mutant-specific antibodies, 119 (381)
MVA-5T4, 188 (601)
Myeloproliferative diseases, 177 (561), 180 (573)
Myofibroblasts, 110 (346)

N

Nab ABI-013, 142 (453)
Nab-rapamycin, 105 (330)
NAD synthesis inhibitors, 116 (367)
NAMPRT inhibitors, 131 (418)
Nanoparticles, 40 (124)
Nanotechnology, 148 (463)
Nanovectors, 173 (550)
Natural killer cells, 166 (524)
NAV3 gene aberrations, 115 (366), 118 (376)
NBDHEX, 106 (333)
NBI-2358, 17 (42)
NCI Comparative Oncology Program, 7 (9)
Nedd8, 113 (356)
Nedd8 activating enzyme (NAE), 29 (85)
Neratinib, 64 (203)
Nerve growth factor, 55 (172)

- Neuroblastoma**, 41 (126), 61 (193), 72 (228, 231), 73 (232), 92 (286), 177 (562)
Nimotuzumab, 160 (505), 168 (530)
NK012, 133 (423)
NK-1 receptor antagonist, 124 (396)
NKG2D, 166 (524)
NKTR-102, 186 (595)
NKTR-105, 141 (448)
Non-Hodgkin lymphoma (NHL), 160 (504), 161 (507)
Non-small cell lung cancer (NSCLC), 33 (97), 34 (101), 64 (203), 68 (215), 99 (309), 112 (353), 119 (381), 123 (392), 126 (401), 138 (439), 140 (445), 141 (448), 450, 160 (505), 169 (535), 174 (552), 184 (588), 185 (592)
NORE1A, 36 (109)
Notch inhibitors, 4 (6)
Notch pathway, 81 (248)
NPI-0052, 73 (234), 74 (235, 236)
NPI-2358, 141 (450)
Nrf2, 158 (496)
NSCLC, *see* **Non-small cell lung cancer**
NTX-010, 60 (191)
Nutlin, 42 (131)
NVP-BE235, 69 (219), 71 (224)
- O**
- Obatoclax**, 115 (364), 185 (592)
Objective response as endpoint, 13 (32)
Oesophageal cancer, 49 (154), 157 (492), 159 (502)
ONYX-411NTR, 96 (300)
OSI-930, 19 (49)
Osteosarcoma, 57 (181), 106 (333)
Ovarian cancer, 39 (119), 54 (168), 68 (214), 87 (268), 126 (400), 143 (455), 153 (478, 481), 158 (495), 159 (501), 162 (512), 163 (513), 164 (519), 169 (536), 184 (590)
OXA-01, 82 (250), 102 (320), 103 (325)
Oxaliplatin, 35 (104), 68 (214), 183 (586)
- P**
- p21**, 35 (104)
p53, 42 (131), 63 (201), 79 (239), 83 (254), 84 (256), 137 (435, 437), 138 (439), 162 (509)
p73, 82 (249)
Paclitaxel, 38 (117), 39 (119), 63 (199), 67 (213), 109 (344), 132 (419), 133 (424, 425), 142 (452), 143 (455), 159 (501)
Paclitaxel-peptide conjugate, 45 (139)
Paediatric Investigation Plan (PIP), 8 (11)
Paediatric malignancies, 61 (193)
Paediatric Regulation (EC), 8 (11)
Paediatric rhabdomyosarcoma, 160 (503)
Pancreatic adenocarcinoma, 27 (77)
Pancreatic cancer, 28 (82), 53 (166), 85 (260), 126 (402), 161 (506), 165 (520), 171 (541), 179 (570), 181 (579), gemcitabine-refractory, 104 (328)
Pancreatic ductal adenocarcinoma (PDAC), 110 (346)
Panitumumab, 81 (247)
Panobinostat, 48 (151), 52 (161), 133 (422)
Papillary cell carcinoma, 22 (63)
PARP, 88 (270)
PARP inhibitors, 80 (245), 154 (482), 175 (555, 557)
Patient selection, 37 (111), 120 (384)
Patupilone, 142 (451), 143 (455)
PBCT, 62 (195)
PBD, 42 (130)
PBD monomers, 60 (189)
PBMCs, 30 (89), 56 (177), 102 (321)
PC3 cell line, 83 (255), 84 (258)
PDGFR, 20 (55), 21 (56), 162 (511), 169 (535)
PDGFR inhibitors, 181 (576), 182 (583), 183 (585)
PDL192, 161 (508)
Pediatric Preclinical Testing Program (PPTP), 8 (12), 9 (14), 60 (190, 191), 61 (192), 92 (286), 176 (558)
PEG linkers, 39 (120), 40 (121)
Pegylated docetaxel, 141 (448)
Pegylated irinotecan, 186 (595)
Pegylated liposomal doxorubicin (PLD), 104 (326)
Pelitinib, 176 (559)
Pemetrexed, 184 (588)
Pendomedine (PEN), 23 (64)
Peripheral neuropathy, 49 (152)
Peritoneal cancer, 162 (512), 164 (519)
PET imaging, 35 (105), 147 (460), 148 (462)
PF-03814735, 91 (282)
PHA-848125, 94 (294)
Phase display, 41 (126)
Pharmacodynamics, 19 (49), 28 (81), 29 (85), 30 (89), 32 (93), 50 (155), 63 (199), 68 (216), 69 (217, 218), 70 (223), 74 (236), 90 (279, 280), 91 (282, 283), 92 (285), 102 (319, 321), 107 (337), 120 (383), 121 (385, 386), 122 (389, 390), 125 (399), 129 (410), 138 (438, 441), 140 (447), 151 (474), 167 (528), 170 (539), 174 (554), 177 (564), 187 (600)
Pharmacogenomics, 9 (16, 17, 18), 10 (19), 61 (194), 62 (195)
Pharmacokinetics, 10 (20), 24 (69), 25 (72), 39 (118), 40 (122), 45 (139), 46 (143), 47 (146), 50 (155), 52 (163), 58 (182), 63 (199), 68 (216), 69 (217, 218), 70 (223), 90 (279, 280), 91 (281, 282, 283), 92 (285), 105 (330), 110 (347), 112 (355), 116 (368), 117 (371), 120 (383), 121 (385, 386), 122 (388, 390), 123 (393), 124 (394, 396), 125 (397, 398, 399), 126 (400), 127 (405, 406), 129 (410), 130 (415), 132 (419, 421), 134 (426, 427), 135 (429, 430), 140 (446), 142 (451), 150 (471), 163 (514), 167 (528), 169 (533), 170 (539), 174 (554), 177 (561, 564), 181 (577), 183 (585), 186 (595), 187 (600)
Pharmacological studies, 62 (197), 81 (1LB), 110 (348), 154 (482), 184 (588)
Phase 0 studies, 10 (20, 21), 81 (1LB), guidelines, 11 (22), industry perspective, 11 (23)
Phase I/II studies, 51 (160), 52 (164), 66 (209), 68 (214), 123 (392), 127 (405), 162 (512), 185 (592), 187 (600)
Phase I studies, 9 (14), 12 (26), 14 (34, 36), 18 (47), 19 (49), 28 (81, 83), 32 (93), 50 (156), 56 (176), 57 (179), 61 (193), 62 (195), 68 (216), 69 (218), 70 (223), 73 (234), 74 (235, 236), 80 (244, 245), 84 (257), 90 (279, 280), 91 (281, 282, 283), 92 (285), 94 (294), 102 (321), 107 (337), 109 (344), 112 (355), 116 (367, 370), 119 (379), 120 (382, 383, 384), 121 (385, 386, 387), 122 (388, 389, 390), 123 (391, 393), 124 (394, 395), 125 (397, 398, 399), 126 (400, 401, 402, 403), 127 (404, 406), 128 (407, 408, 409), 129 (410, 411), 130 (413, 414), 131 (416, 417, 418), 132 (419, 420, 421), 133 (422, 423, 424, 425), 134 (426, 427, 428), 135 (429, 431), 138 (438), 140 (446), 150 (471), 153 (480), 162 (510, 511), 174 (554), 177 (564), 183 (585), 186 (594, 595), 188 (601)
Phase II studies, 12 (28), 13 (31), 17 (42), 20 (53), 33 (97), 42 (130), 50 (156), 64 (203, 204), 65 (205, 206, 207), 66 (208), 67 (210, 211, 212, 213), 81 (2LB), 92 (286),

Phase II studies (*cont'd*)

104 (328), 107 (338), 121 (385), 126 (401), 157 (494),
160 (505), 163 (514), 164 (519), 178 (565), 188 (601)

parallel trials, 12 (29)

patient enrichment, 13 (30)

Phase III studies, 62 (195), 102 (321), 157 (494), 184 (588)

Phyllanthus pulcher, 58 (184)

Picoplatin, 67 (210, 211)

Picornavirus, 60 (191)

PI3K, 30 (89), 32 (94), 68 (216), 69 (217, 218, 219), 70 (221,
223), 71 (225, 226, 227), 72 (228, 229, 230), 147 (457)

isoforms, 4 (5)

PI3K/Akt/mTOR pathway, 71 (227), 102 (320), 103 (323)

PI3K/Akt pathway, 54 (169, 170), 70 (222), 112 (354),
163 (515)

PI3K/PTEN pathway, 162 (509)

Pim kinases, 105 (332)

PKC inhibitors, 126 (401), 182 (581)

Plasma sampling, 33 (97), 36 (108)

Plasma Trx-1, 36 (108)

PLX4032, 185 (591)

PM00104, 57 (179), 61 (193)

PM02734, 57 (181), 101 (317)

Polo kinases, 80 (244), 135 (430, 431), 136 (432, 433, 434)

Polyethyleneimine (PEI) complexes, 96 (299), 97 (301)

Polyubiquitination, 99 (310)

PPAR γ agonists, 115 (365)

PPAR γ antagonists, 128 (409)

PR-00299804, 177 (564)

PR-104, 96 (300), 151 (473, 474)

Pre-clinical studies, 7 (7), 24 (67), 28 (83), 36 (108), 48 (150),
69 (217)

Predictive markers, 9 (18), 17 (43), 27 (77), 29 (84), 31 (91),
33 (99), 34 (101), 55 (174), 63 (198), 118 (376),
155 (488)

Prednisolone, 142 (451)

Prednisone, 66 (209), 67 (211)

Premetastatic niches, 55 (171)

Prodrugs, 35 (104), 96 (300), 97 (304), 98 (305), 105 (331),
122 (389), 129 (412), 135 (429), 150 (468, 470),
151 (473, 474)

CYP-activated, 11 (25)

Prognostic markers, 9 (18), 29 (86), 32 (94), 34 (100, 101,
102), 147 (457), 150 (468), 154 (483), 167 (526),
173 (549)

ProLindac, 35 (104), 46 (143), 68 (214)

Prostate cancer, 16 (39), 18 (45), 58 (183, 184), 59 (188),
85 (262), 103 (324), 112 (354), 140 (445), 157 (493),
165 (520), 173 (548), 175 (555), 188 (601)

castration resistant, 12 (26), 39 (118), 50 (157), 51 (158, 159,
160), 52 (162), 81 (2LB), 178 (565)

hormone-dependent, 35 (105)

hormone-refractory, 7 (7), 39 (118), 52 (161), 66 (209),
67 (211), 83 (255), 98 (307), 108 (340), 126 (400)

taxane resistant, 139 (443)

Protacs, 16 (39)

Proteasome inhibitors, 15 (38), 24 (68), 49 (152), 72 (231),
73 (232, 233, 234), 74 (235, 236, 237), 75 (238),
121 (385)

Proteasome-lysosome trafficking, 99 (310)

Protein-protein interactions, 44 (135), 82 (251), 137 (435,
436)

Proteomics, 7 (10), 34 (101), 159 (500), 165 (522), 172 (544)

PTEN, 51 (158), 70 (221), 103 (324), 147 (457), 162 (509),
164 (516), 179 (572)

Puma, 86 (266)

Pyrazine scaffold, 183 (584)

Pyrazolopyrimidines, 178 (566), 180 (574)

Pyrazoloquinazoline derivatives, 136 (434)

Pyrrrolotriazines, 93 (290)

Q

QBI-139, 110 (347)

QTc formulae, 120 (384)

Quantum dots, 34 (102)

Quiescent cells, 86 (263)

R

RAD001, 103 (323), 104 (326, 328)

Radiolabelling, 14 (33), 148 (462)

Radiosensitisation, 172 (546)

Radiotherapy, 25 (71), 49 (154), 65 (207), 142 (454),
160 (505), 168 (530)

RAF265, 103 (323)

Raf inhibitors, 183 (587), 185 (591)

RAF/MAPK pathway, 103 (323)

RAMBAs, 12 (27)

Rapamycin, 60 (190), 102 (319, 320), 185 (593)

RAS mutations, 178 (567)

RAS/RAF/MEK/ERK pathway, 33 (99)

RAS/RAF pathway, 103 (323), 162 (509)

RDEA119, 181 (577)

RECIST, 13 (32)

Relational database management systems, 61 (194)

Renal cell carcinoma (RCC), 20 (52), 22 (61), 41 (125),
64 (204), 71 (224), 104 (329), 114 (360), 128 (408),
171 (542), 188 (601)

Reovirus, 95 (297), 99 (308)

RET, 126 (402), 184 (588)

RET inhibition, 3 (3)

Retinoblastomas, 116 (369)

RGB-286638, 181 (578)

Rhabdomyosarcoma, 57 (181), 61 (193), 160 (503)

rhEGF, 87 (269)

RhoA/B, 182 (580)

RHPS4, 138 (440, 441)

Ricin, 122 (389)

ril-21, 116 (370), 128 (408)

Rituximab, 26 (74), 97 (303), 161 (507), 167 (526)

RNA interference, 147 (456, 458, 459), 174 (551)

RNA polymerase, 94 (292)

RNA polymerase inhibitors, 108 (341)

RNAi screening, 70 (222)

RNase technology, 110 (347)

Ror2, 114 (360)

Rosiglitazone, 115 (365)

RT-PCR, 173 (549)

RTK inhibitors, 17 (43)

S

S23906, 159 (500)

Safingol, 182 (581)

SAHA, 84 (257), 88 (271)

Salinosporamides, 74 (237)

Sapacitabine, 150 (469)

SAR3419, 61 (192)

SAR566658, 166 (525), 169 (533)

Sarcoma, 122 (388)

SB939, 28 (83), 44 (136), 130 (413)

SB-743921 (SB-921), 128 (407)

Schweinfurthin A, 57 (178)

Scr inhibitors, 180 (575)

SDS-PAGE, 117 (372)

- SEK1**, 183 (586)
Serum autoantibodies, 34 (101)
SF1126, 72 (229)
sFLT01, 18 (48)
SG2313, 60 (189)
SGI-1252, 179 (571)
SGI-1776, 105 (332)
SGN-35, 166 (523)
SGX126, 177 (563)
SHOP-2005 protocol, 63 (198)
Sibiromycin, 60 (189)
Signaling pathways, 7 (10)
Single nucleotide polymorphism (SNP), 10 (19)
siRNA, 147 (456), 173 (548, 550)
Smac mimetics, 42 (129)
Small cell lung cancer (SCLC), 93 (288), 98 (306), 115 (364)
SN-38, 133 (423), 134 (427), 187 (597)
SOD silencing, 52 (162)
Sodium meta-arsenite, 110 (348)
Soft tissue sarcomas, 132 (420)
Sorafenib, 24 (68), 64 (204), 129 (410)
SPC3920, 97 (302)
SPECT, 148 (462)
S1P1R, 106 (335)
Src inhibitors, 123 (391)
SRJ09, 43 (132)
STAT3, 114 (362), 118 (377)
STAT-3 inhibitors, 45 (138)
Steroid hormone receptors, 16 (39)
Structure analysis, 44 (135, 136, 137), 45 (141), 46 (144), 59 (185), 60 (189), 74 (237), 82 (251), 93 (287), 105 (331), 106 (334), 136 (433, 434), 137 (436), 154 (484), 173 (550), 176 (560)
Structure–activity relationships, 41 (127), 42 (130), 70 (221), 98 (305), 176 (560)
SU11248, 27 (78)
SUCCEED study, 102 (321)
Suicide genes, 98 (306)
Suicide prodrugs, 150 (468)
Sunitinib, 22 (61), 25 (70), 65 (206), 66 (208), 67 (212), 128 (408)
Supercoiled DNA, 114 (362)
Syrbactins, 72 (231)
- T**
T-cell lymphomas, 168 (532)
TAK-285, 27 (78), 99 (311), 100 (313, 314)
TAK-593, 19 (50, 51), 21 (56)
Tamoxifen, 155 (488), 158 (497), 184 (589)
Tanespimycin, 49 (152)
***Taraxacum officinale* (dandelion)**, 172 (547)
Targeted therapies, 3 (2, 4), 4 (6), 11 (24), 12 (29), 17 (44), 18 (45), 19 (49), 20 (52, 53), 21 (58), 27 (80), 28 (81, 82), 30 (88), 34 (100, 103), 36 (107, 110), 38 (114), 39 (120), 40 (121, 123), 41 (126), 42 (129), 43 (132), 45 (138, 140), 49 (154), 53 (166), 54 (168, 169, 170), 55 (172, 173), 59 (185), 61 (194), 72 (228), 74 (236), 79 (241, 242), 80 (246), 81 (248), 82 (249, 251), 83 (252, 253, 254), 84 (256), 88 (271), 93 (287), 97 (301), 98 (306), 115 (363), 117 (371, 374), 118 (378), 128 (409), 138 (441), 147 (460), 149 (466, 467), 161 (506), 162 (511), 166 (524), 169 (536), 170 (538, 539), 171 (542, 543), 172 (544), 173 (548), 174 (551, 553), 178 (566)
TAS-102, 134 (428)
Taxanes, 140 (445), 142 (452)
- Taxol**, 68 (214), 87 (268)
Telomerase inhibitors, 138 (438, 439, 440, 441), 139 (442), 158 (497)
Telomeres, 43 (134)
TEM, 168 (531)
Temozolomide, 79 (240), 153 (479), 155 (486), 175 (555), 177 (562), 186 (596)
Temsirolimus, 104 (329)
TETRAC, 172 (546)
TGF- β 1, 110 (346)
TH-302, 129 (412)
Thymidylate synthase (TS), 101 (318)
Thyroid cancer, 3 (3)
Titanocene analogues, 157 (493)
TLN-4601, 181 (579)
TMPyP4, 116 (369)
TM9SF2, 36 (110)
Topoisomerase inhibitors, 156 (489), 186 (596), 187 (598)
Topoisomerase mutations, 187 (597)
TP300, 186 (594)
TPI inhibitors, 134 (428)
TRAIL, 84 (259), 85 (260), 87 (267), 98 (307)
Translation initiation, 83 (252, 253)
Trastuzumab, 147 (457), 168 (531)
Trastuzumab-mertansine, 163 (515)
TRC093, 130 (414)
TRC105, 126 (400)
Treatment outcome, 13 (32)
Trial design, 3 (1, 2, 3), 10 (21), 12 (29), 46 (143), 121 (387), 174 (552)
Triple negative breast cancer, 175 (557)
Triptolide, 56 (175)
Trk inhibitors, 180 (574)
Trop-2, 117 (371), 165 (520), 171 (543)
TroVax, 188 (601)
TrpM8, 109 (343)
Trypterygium wilfordii, 56 (175)
TST10088 (TST88), 122 (389)
TSU-68, 17 (43)
Tubulin-interacting agents, 139 (443, 444), 140 (445), 141 (449), 142 (452)
Tumorigenesis, 16 (40)
Tumour-associated macrophages (TAMs), 113 (359)
Tumour classification, 22 (63)
Tumour-derived membrane vesicles (TMV), 96 (298)
Tumour vasculature, 18 (46, 48)
 homing peptide, 21 (58)
 vascular disrupting agents, 32 (96)
Tumour–stromal cell interaction, 59 (188), 179 (570)
TWEAK receptor, 161 (508)
TZP-101, 107 (338)
- U**
U3-1287 (AMG 888), 99 (309)
UGT0601 trial, 121 (387)
UNBS5162, 18 (47)
Urothelial cell carcinoma, 35 (106)
Ursodeoxycholic acid, 38 (114)
Uveal melanoma, 24 (67)
- V**
Vaccines, 188 (601, 602)
Vandetanib, 39 (119), 126 (402), 184 (588)
Vascular disrupting agents, 32 (96)
VEGF, 14 (33), 17 (44), 18 (45, 48), 19 (50, 51), 20 (54), 23 (65), 65 (206), 126 (402), 176 (558)

VEGF inhibitors, 180 (575)

VEGF, 172 (545)

irradiation-induced, 172 (545)

VEGF receptors, 18 (46), 20 (52, 53, 55), 21 (56), 28 (81),
30 (87), 127 (406), 171 (542), 184 (588)

inhibitors, 124 (394)

Vinca alkaloids, 141 (449)

Vincristine, 60 (190)

Vinorelbine, 141 (449)

VLA-4 antagonists, 111 (352)

Volociximab, 162 (512), 164 (519)

Voreloxin, 153 (478), 187 (598)

Vorinostat, 104 (329), 111 (349)

W

Warburg effect, 27 (80)

Wnt signaling pathway, 113 (357)

X

Xenografts, 8 (12, 13), 20 (55), 24 (67, 69), 25 (70, 71, 72),
26 (73, 74, 75), 27 (77, 79), 29 (85), 30 (87), 31 (91),
35 (105), 38 (117), 39 (119), 40 (121), 47 (145), 48 (150),
50 (155, 157), 52 (164), 57 (180), 60 (191), 62 (197),
68 (216), 71 (225, 226), 75 (238), 82 (250), 92 (284, 286),
94 (292, 294), 95 (297), 97 (303), 99 (309), 101 (315),

102 (319), 104 (329), 105 (331), 106 (335), 107 (337,
338), 108 (342), 112 (353), 114 (360), 115 (365),
127 (406), 129 (412), 140 (445), 141 (448, 449, 450),
142 (453), 143 (455), 150 (470), 151 (474), 160 (504),
164 (517, 518), 165 (520), 166 (525), 167 (529),
168 (531), 169 (533, 535), 175 (555, 556), 176 (558),
177 (561, 562), 179 (570), 185 (591), 186 (594, 596)

XIAP inhibitors, 85 (260), 87 (267), 98 (307)

XL147, 69 (218)

XL184, 119 (379)

XL281, 120 (383)

XL288, 122 (390)

XL413, 108 (339)

XL765, 68 (216)

XL820, 67 (212)

XL844, 124 (395)

XL888, 46 (144)

Y

Y27632, 37 (113)

YM155, 112 (353)

YM753, 108 (340)

Z

ZSTK474, 71 (225, 226)